| abstract |
The invention relates to medicine, in particular to oncology and molecular biology and can be used for the earlier diagnosis of the prostate pathologies, including prostate cancer by means on a non-invasive method. The invention is characterised in that recombinant protein hepsin, produced from a pHPNTM -A N°B- 100978 producer strain, is used as an agent for verifying the reaction quality in the test system, in that 0.1M tris-imidazole is used as a reaction buffer for reaction verification and setting, in that tetrapeptide L-lysine P2 Р3 L-arginine, wherein P2 - L-asparagine or L-leycine or L-threonine, P3 - L-lysine or L-glutamine conjugated with chromogen, is used as a substrate, in that the prostate cancer presence and the stage thereof are ascertained according to the hepsin Ao activity in nmol/l⋅min which is determined according to the mean value ΔЕо/minute of the change rate per minute of the density of a treated urine sample containing the substrate and the reaction buffer added thereto, wherein the test results obtained when the activity of a check hepsin Ak, verified with the aid of the same test-system, differs from the reference values Ae by more than 10%, were excluded |